Zoran Lalic
Dalibor Petrovic
Zeljko Saravanja
ATACOR RE-LAUNCHED FROM OUR EU-GMP SITE IN LESKOVAC
Weโre excited to announce that ๐๐ฟ๐ผ๐ป๐๐ถ๐ฒ๐ป๐ ๐ฐ๐ฌ๐ฌ๐บ๐ด (๐๐ก๐ก: ๐ฃ๐ฎ๐๐ผ๐ฝ๐ฎ๐ป๐ถ๐ฏ) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans โ a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.
DERMIFIN JOINS OUR OTC LINEUP
Weโre excited to announce that ๐๐ฟ๐ผ๐ป๐๐ถ๐ฒ๐ป๐ ๐ฐ๐ฌ๐ฌ๐บ๐ด (๐๐ก๐ก: ๐ฃ๐ฎ๐๐ผ๐ฝ๐ฎ๐ป๐ถ๐ฏ) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans โ a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.
Leading The Way: Interview with Sanja Spasojevic, Business Development Director – CDMO
Weโre excited to announce that ๐๐ฟ๐ผ๐ป๐๐ถ๐ฒ๐ป๐ ๐ฐ๐ฌ๐ฌ๐บ๐ด (๐๐ก๐ก: ๐ฃ๐ฎ๐๐ผ๐ฝ๐ฎ๐ป๐ถ๐ฏ) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans โ a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.